This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
5 Cancer-Fighting Stocks to Add to Your Portfolio
by Zacks Equity Research
Cancer-fighting stocks receive a boost from advance research and development. These five stocks can add value to your portfolio.
5 Top S&P 500 Stocks Soaring Despite Worst August Since 2015
by Nalak Das
Despite the presence of severe volatility, a few top-ranked stocks, within the broad-market S&P 500 Index, climbed in August.
Bristol-Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Bristol-Myers Squibb (BMY) closed at $48.07 in the latest trading session, marking a -0.41% move from the prior day.
The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Alamos Gold, Americold Realty Trust, TransDigm and frontdoor
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Alamos Gold, Americold Realty Trust, TransDigm and frontdoor
The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, ONEOK, Verizon Communications, Principal Financial and Omnicom
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, ONEOK, Verizon Communications, Principal Financial and Omnicom
Pharma Stock Roundup: JNJ's Opioid Lawsuit, Regulatory Nod for LLY, BMY, RHHBY Drugs
by Kinjel Shah
Oklahoma imposes fine of $572 million on J&J (JNJ). FDA gives nod to Lilly's (LLY) Taltz while EU approves Bristol-Myers' (BMY) Empliciti and Roche's (RHHBY) Tecentriq for expanded patient population.
5 Top Momentum Stocks in August Despite Market Mayhem
by Nalak Das
Despite several stock market negatives, a few stocks have surged in August and still carry strong momentum for further upside.
Will Treasury Yield Inversion Benefit Stocks? 5 Top Picks
by Nalak Das
At this stage, investment in high-yielding, S&P 500 stocks, which pay out regular dividend, will be a prudent move.
What Investors Need to Know About the Celgene, Amgen & Bristol-Myers Deals
by Mitchell Moore
On Monday, Celgene (CELG) announced a sale of its psoriasis drug Otezla for $13.4 billion to Amgen (AMGN). This deal will be all cash and is expected to clear before the end of the year. Celgene's stock climbed 3.2% the day of the announcement and has risen another 0.5% since then.
The Zacks Analyst Blog Highlights: Bristol-Myers Squibb Company, Celgene, Exact Sciences, Pfizer and Guardant Health
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bristol-Myers Squibb Company, Celgene, Exact Sciences, Pfizer and Guardant Health
Bristol-Myers' Empliciti Gets EMA Nod for Label Expansion
by Zacks Equity Research
Bristol-Myers' (BMY) multiple myeloma drug, Empliciti gets approval in Europe in combination with Celgene's Pomalyst in third or later-line settings.
Alexion Wins EC Nod for Soliris in Nervous System Disorder
by Zacks Equity Research
Alexion (ALXN) receives EC approval for the label expansion of lead drug, Soliris, for the indication of rare, devastating disorder of the central nervous system.
Amgen to Buy Celgene's Otezla for $13.4B: Is it a Good Buy?
by Zacks Equity Research
Amgen's (AMGN) purchase of Celgene's blockbuster psoriasis drug, Otezla is likely to strengthen its position in the immunology space.
Amgen to Buy Celgene's Otezla: 5 ETF Drugs
by Sweta Killa
Amgen agreed to buy psoriasis and psoriatic arthritis drug Otezla from Celgene for $13.4 billion in cash.
3 Cancer Treatment Stocks to Enrich Your Portfolio
by Tirthankar Chakraborty
Investments in cancer therapies are expected to rise almost $250 billion by 2023, from $150 billion in 2018. Thus, companies that are coming up with innovative methods to cure this malaise are great investment choices.
Alexion (ALXN) Down 3.2% After Amgen Buys Otezla From Celgene
by Zacks Equity Research
Alexion's (ALXN) shares dip after gaining steam on rumors of a potential acquisition by Amgen last week.
Bristol-Myers Announces Sale of Celgene's Otezla to Amgen
by Zacks Equity Research
Bristol-Myers (BMY) announces that Celgene will sell psoriasis drug, Otezla, to Amgen in connection with the ongoing regulatory approval process.
Why Is Bristol-Myers (BMY) Up 2.6% Since Last Earnings Report?
by Zacks Equity Research
Bristol-Myers (BMY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Roche's Tecentriq Gets Japan's Nod for Small Cell Lung Cancer
by Zacks Equity Research
Roche (RHHBY) gets approval for Tecentriq in Japan for extensive-stage SCLC.
Retrophin Down on Neurological Disorder Drug Study Failure
by Zacks Equity Research
Retrophin (RTRX) declines as the late-stage study on a rare neurological disorder candidate failed to achieve its main goal.
The Zacks Analyst Blog Highlights: Home Depot, Abbott, Bristol-Myers, Activision and Marathon
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Home Depot, Abbott, Bristol-Myers, Activision and Marathon
The Zacks Analyst Blog Highlights: Walt Disney, AngloGold, Vipshop, Bristol-Myers and Integer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Walt Disney, AngloGold, Vipshop, Bristol-Myers and Integer
The Zacks Analyst Blog Highlights: AngloGold, Bristol-Myers, Delta Air, JD.com and M/I Homes
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AngloGold, Bristol-Myers, Delta Air, JD.com and M/I Homes
AstraZeneca's Imfinzi Fails in Stage IV Lung Cancer Study
by Zacks Equity Research
AstraZeneca's (AZN) Imfinzi fails to improve overall survival in a study for previously treated stage IV non-small cell lung cancer (NSCLC) patients.
Top Stock Reports for Home Depot, Abbott & Bristol-Myers
by Mark Vickery
Today's Research Daily features updated research reports on 16 major stocks, including Home Depot (HD), Abbott (ABT) and Bristol-Myers (BMY).